Gudrun Simons

Learn More
Empagliflozin is an orally available, selective inhibitor of sodium glucose cotransporter 2. In this study, single oral doses of empagliflozin from 0.5 to 800 mg were not associated with any clinically significant safety concerns in healthy male volunteers. The incidence of adverse events (AEs) was similar in subjects receiving placebo (22.2%) or(More)
BACKGROUND Empagliflozin is a potent, selective sodium glucose cotransporter 2 (SGLT2) inhibitor in development as an oral antidiabetic treatment. This QT interval study assessed potential effects of empagliflozin on ventricular repolarisation and other electrocardiogram (ECG) parameters. METHODS A randomised, placebo-controlled, single-dose,(More)
Protein concentrations in gingival fluid exudate were obtained in both the clinically minimal and severe inflammatory states. A comparison of the results indicated no significant differences in the two groups studied. Since total protein concentrations do not appear to reflect accurately the clinical inflammatory status of the gingival tissues, specific(More)
In the last few years, the possible connection between the use of oral contraceptives and benign hepatocellular tumors and focal nodular hyperplasia of the liver has been discussed. Spontaneous rupture with hemoperitoneum characterizes the main problem of treatment. The high risk of hemorrhage and the possibility of the existence of a malignant tumor demand(More)
  • 1